Financial Data and Key Metrics Changes - AMERISAFE reported net income of $13.2 million or $0.69 per diluted share for Q4 2024, down from $19.2 million or $1 per diluted share in Q4 2023 [13] - For the full year, net income was $55.4 million compared to $62.1 million in 2023, while net operating income decreased to $48.4 million from $55.9 million [14] - The combined ratio improved to 88.7% with a return on equity (ROE) of 20.2% [8][11] Business Line Data and Key Metrics Changes - Gross premiums written increased by 3.9% in Q4 and 3.1% for the full year, with voluntary premiums rising by 8.5% in Q4 and 4.6% for the year [6] - The enforced policy count grew by 9.6% for the year, indicating strong premium retention and new business production [6][7] Market Data and Key Metrics Changes - The accident year loss ratio remained steady at 71%, consistent with the prior year, with favorable development from prior accident years amounting to $9.7 million in Q4 and $34.9 million for the full year [10] - The investment portfolio's net investment income decreased by 14.4% to $6.9 million for Q4 and by 6.8% to $29.2 million for the full year [17] Company Strategy and Development Direction - The company is focused on top-line growth while maintaining consistent underwriting margins, emphasizing the importance of agent relationships and a sales-driven culture [6][8] - AMERISAFE aims to identify and ensure profitable high-risk, high-hazard risks to offset broader market challenges [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate a competitive landscape and maintain strong policy retention [11][79] - The outlook for the construction industry remains positive, with expectations of continued payroll growth and opportunities for business [74][79] Other Important Information - The Board of Directors approved a 5.4% increase in the regular dividend to $0.39 per share [11] - The company reported a book value per share of $13.51 after paying a special dividend, reflecting an 11.6% decrease from year-end 2023 [21] Q&A Session Summary Question: Can you provide context for the 9.6% policy count growth? - Management clarified that the 9.6% growth was for the entire year, with a 2.6% growth in the fourth quarter [24][28] Question: How has the average policy size trended? - The average policy size for 2024 was slightly lower than in 2023, with a noted decrease in average wages in Q4 [34] Question: What impact did renewal rates have on the top line? - Renewal rates were strong, with a policy retention rate of 94.1% on a policy basis and 88% on a premium basis [37] Question: How are claims from prior years developing? - Favorable development from prior accident years was noted, with significant contributions from 2022 and earlier years [39] Question: What is the outlook for the construction industry? - Management believes the construction industry remains strong, with payroll growth and opportunities for business despite potential economic challenges [74][79] Question: How many large claims were there in 2024? - The company reported 18 claims over a million dollars, which is consistent with the five-year average [81] Question: Any updates on medical inflation and reimbursement rates? - No significant changes were noted, but home health costs remain a focus due to their impact on larger claims [86] Question: What is the outlook for audit premiums? - Management expects audit premiums to remain positive in 2025, despite potential deceleration in year-over-year comparisons [102] Question: Have competitors become more aggressive in the workers' comp market? - The market remains competitive, but AMERISAFE is prepared to handle competitors entering the high hazard space [104]

Financial Data and Key Metrics Changes - Ambac reported a net loss of $548 million or $10.23 per diluted share for Q4 2024, compared to a net loss of $16 million or $0.24 per diluted share in Q4 2023 [28] - Consolidated adjusted net loss was $6 million or $0.12 per diluted share for Q4 2024, compared to adjusted net income of $4 million or $0.10 per diluted share in Q4 2023 [30] - The company recorded a $570 million loss on the sale of its legacy financial guarantee business [23] Business Line Data and Key Metrics Changes - The P&C business generated nearly $900 million in premiums, up 74% from 2023, and produced $236 million in revenue, up 89% from the prior year [7] - Cirrata generated nearly $100 million in revenue for 2024, up 93%, and earned approximately $20 million of adjusted EBITDA [15] - Everspan's gross premium written grew to over $380 million, up 40% from the prior year, with a combined ratio of 101.6%, improving nearly 500 basis points over 2023 [20][21] Market Data and Key Metrics Changes - The overall E&S market continues to perform well, with high-single to double-digit rate increases in U.S. casualty lines [12] - The property market showed some softening in Q4, but terms and conditions have held [13] - Professional and financial lines are experiencing softness, particularly in large account and public market D&O [14] Company Strategy and Development Direction - The company is focused on the future growth of its Specialty P&C business and delivering value for shareholders [11] - Ambac aims to achieve strong organic growth and generate $80 million to $90 million of adjusted EBITDA to common shareholders by 2028 [44] - The acquisition of Beat is expected to deliver strong organic growth and enhance the distribution platform [8] Management's Comments on Operating Environment and Future Outlook - Management noted that the areas of softening in the market, such as Employer Stop Loss and short-term medical, may stabilize in the near future [50] - The focus remains on profitability for Everspan, with effective loss ratios in the mid-60s aligning with long-term goals [55] - Management expressed optimism about the prospects for Ambac's future, particularly following the separation from the legacy financial guarantee business [43] Other Important Information - The company has substantially completed the separation of its legacy and P&C businesses, preparing for the close of the legacy sale [11] - Cirrata's premiums increased by 309% to $205 million, with total revenue rising by 257% to $44 million compared to Q4 2023 [31] Q&A Session Summary Question: Distribution business performance and outlook - Management indicated that softening in Employer Stop Loss and short-term medical is a macro trend, but stabilization is expected [50][51] Question: Sustainability of Everspan's combined ratio - Management stated that while there is variability, the performance aligns with long-term objectives, aiming for effective loss ratios in the mid-60s [55][56]